阿托伐他汀抑制胶质瘤细胞U87侵袭性及相关机制研究  

Study of atorvastatin on mechanism of inhibiting invasion in glioma U87 cells

作　　者：贾熙卓 郑天虎[1] 李艳泽[1] 刁岩[1] 高旭[1] 

机构地区：[1]哈尔滨医科大学生物化学与分子生物学教研室,150081

出　　处：《国际遗传学杂志》2014年第3期103-108,共6页International Journal of Genetics

摘　　要：目的探讨阿托伐他汀（AVT）对人胶质瘤细胞U87侵袭性的抑制作用及其相关机制的研究。方法采用Transwell法检测AVT抑制胶质瘤细胞侵袭的效率，RT-PCR和Western印迹方法检测AVT对CXCL12和CXCR4表达的影响。结果RT-PCR实验结果表明AVT作用一定时间（24h），随着AVT浓度增大，CXCR4mRNA表达量逐渐减小。AVT浓度为1．0、2．0、8．0μmol／LAVT与未加AVT对照组差异具有统计学意义（P值分别为0．045、0．021、0．002）；在AVT浓度一定时（2．0μmol／LAVT），AVT作用时间越长，CXCR4mRNA表达量越小。AVT作用时间为12、24、36h与未加AVT对照组差异具有统计学意义（P值分别为0．040、0．019、0．001）。AVT对CXCL12mRNA表达影响不显著，与对照组差异无统计学意义（P值为0．869）。结论AVT能够显著抑制胶质瘤细胞U87的侵袭性，并且抑制趋化因子CXCR4的表达水平，AVT可能通过下调CXCR4的表达从而抑制胶质瘤细胞的侵袭性。Objective To explore the mechanism of atorvastatin （AVT） on inhibition of invasion in glioma U87 ceils. Methods To detect the efficiency of AVT on inhibition of the invassion of glioma cells by using Transwell kit, RT- PCR and Western blot methods were used to study the effects of AVT on CXCL12 and CXCR4 expression. Results The results showed that the effect of atorvastatin （AVT） , after 24 hour treatment, is an dose-dependent decrease in CXCR4 mRNA expression with the increasing concentration of atorvastatin. Compared with control group, the cells treated with 1.0, 2.0, 8.0 μmol/ L AVT have showed statistically significant changes （P values are 0. 045, 0. 021, 0. 002 respectively）. At the same concentration of AVT （2.0 μmol/ L ） , the expression level of CXCR4 mRNA decreased, following a time-dpendent manner （12, 24, 36 hours ） , and being statistically significant （P values are 0. 040, 0.019, 0.001 respectively ）. The AVT administration does not have effects on the expression of CXCL12 mRNA, statistically, with P value being 0. 869. Conclusion AVT significantly inhibited the invasion of glioma U87 cells clinically, and inhibited the expression of CXCR4 experimentally. There- fore we speculate that the AVT maybe inhibit glioma cell invasiveness through downregnlation of CXCR4 expression.

关 键 词：胶质瘤 阿托伐他汀 趋化因子受体4 趋化因子12 

分 类 号：R739.4[医药卫生—肿瘤]